Showing results (561-570 of 661) with videos related to

Sort By:
Pageof 67
Journal of Cancer Research and Clinical Oncology|March 21, 2021
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysisAndrea Casadei-Gardini, Lorenza Rimassa, Margherita Rimini, et al.
Biogerontology|January 30, 2015
Population-specific association of genes for telomere-associated proteins with longevity in an Italian populationPaolina Crocco, Roberto Barale, Giuseppina Rose, et al.
Neurochemical Research|April 21, 2015
Antidepressant Effects of Ketamine Are Not Related to ¹⁸F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar RatsPedro Porto Alegre Baptista, Lisiani Saur, Pamela Bambrilla Bagatini, et al.
Revista Brasileira De Epidemiologia = Brazilian Journal of Epidemiology|October 10, 2019
Prevalence of altered total cholesterol and fractions in the Brazilian adult population: National Health SurveyDeborah Carvalho Malta, Celia Landman Szwarcwald, Ísis Eloah Machado, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2022
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN studyMario Rizzato, Stefano Brignola, Giada Munari, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancerLetizia Procaccio, Francesca Bergamo, Maura Gatti, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
The Lancet. Oncology|December 8, 2018
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trialGiuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, et al.
Clinical Colorectal Cancer|August 29, 2018
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR StudyMarta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, et al.
Journal of Neuro-Oncology|October 15, 2025
Incidence and survival of adult central nervous system tumors in the Veneto region: a population-based registry study (2016-2020)Alessandra Andreotti, Eliana Ferroni, Stefano Guzzinati, et al.
Pageof 67